Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $26.61, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq increased by 0.81%.Heading into today, shares of the company had lost 11.43% over the past month, lagging the Medical sector's loss of 2.82% and the S&P 500's gain of 4.61% in that time.Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.44, showcasing a 120% downward movement from the corresponding quarter of the prior year.Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold).The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 31% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks